Long-Term IPF Treatment with OFEV® (Nintedanib) Shown to Remain Effective and Without New Safety Concerns

Long-Term IPF Treatment with OFEV® (Nintedanib) Shown to Remain Effective and Without New Safety Concerns

New data from the analysis of trial INPULSIS™-ON, describing the long-term efficacy and side-effects of OFEV in the treatment of idiopathic pulmonary fibrosis (IPF), was presented at the European Respiratory Society (ERS) International Congress 2015. IPF is a type of interstitial lung disease, affecting the tissue that supports the alveoli…

Improvements and Obstacles: How Is IPF Treatment Advancing?

Sixty-six year old Dan Castner was living life to the fullest when he started experiencing difficulties in breathing. While he worked in the outdoor industry for more than 40 years and was used to biking, climbing, camping, skiing and hiking, in March of 2012 his life completely changed. Castner was diagnosed with…

Researchers Discuss Idiopathic Pulmonary Fibrosis Comorbidities

A team of researchers from the Department of Clinical and Experimental Medicine at the University of Catania, Italy recently reviewed the co-occurrence of additional diseases in Idiopathic Pulmonary Fibrosis and their current therapeutic strategies. The study, entitled “IPF, comorbidities and management implications,“ was published in the Sarcoidosis Vasculitis and…

MediciNova’s IPF Treatment MN-001 Receives US FDA Fast Track Designation

MediciNova, Inc., a biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the US Food and Drug Administration has granted its leading product candidate for idiopathic pulmonary fibrosis (IPF) a Fast Track Designation. This follows the agency’s October 2014 decision to grant…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums